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ABSTRACT 
Objective: Human fetuin/2-HS-glycoprotein (AHSG) is a 49 kD serum and 
tissue protein, which is a natural inhibitor of insulin receptor signaling. We 
investigated serum AHSG levels during pregnancy and whether the protein is 
involved in insulin resistance observed in healthy pregnant women and patients 
with gestational diabetes. 
Design: One hundred and four healthy pregnant women and 23 of their neonates, 
30 patients with gestational diabetes and their neonates and 30 healthy 
age-matched non-pregnant females as a control group were investigated in a 
case-control cross-sectional study. 
Methods: Serum AHSG was determined by radial immunodiffusion. 
Results: We observed an increase of serum AHSG concentration in the second 
and third trimester. Gestational diabetes patients had significantly higher AHSG 
levels than healthy pregnant women and non-pregnant controls. There was a 
highly significant positive correlation between serum AHSG concentration and 
indirect parameters of insulin resistance, i.e. tumor necrosis factor- (TNF-), 
leptin, C-peptide, and C-peptide/blood glucose ratio. There was also a negative 
correlation between maternal AHSG, TNF-, leptin levels and head 
circumference, body length and body weight of newborns. 
Conclusion: AHSG, TNF- and leptin may contribute to insulin resistance 
during normal pregnancy and gestational diabetes. AHSG along with these 
cytokines may also negatively regulate the neonatal skeletal development. 
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Introduction 
 
Human fetuin/2-HS-glycoprotein (AHSG) is a 49 kD serum and tissue protein, 
which plays a role in the host defense and bone metabolism [1, 2]. The protein is 
one of the major components of the non-collagenous bone matrix, especially in 
the fetal age. The main source of its serum isoform is the liver, where its 
phosphorylated variant decreases the signal transduction of the insulin receptor; 
hence, it may contribute to the cellular insulin resistance [3, 4, 5]. The tumor 
necrosis factor (TNF) system [6] and leptin [7] were also found to contribute to 
insulin resistance in obesity and Type 2 diabetes, and may influence the insulin 
secretory capacity of the -cells, too. Both cytokines may also be involved in the 
intrauterine bone development [8, 9]. 
 
Progressive increase in insulin resistance has repeatedly been demonstrated 
during the course of the normal pregnancy [10]. Decreased insulin sensitivity is 
even more pronounced in patients with gestational diabetes [11]. The status of 
hepatic insulin sensitivity in pregnancy and gestational diabetes is less clear. 
Studies on pregnant rats described an increased hepatic insulin resistance [12]. 
Because of its established role in signal transduction of the insulin receptor we 
studied the potential contribution of AHSG in insulin resistance accompanying 
normal pregnancy and GDM. 
 
It can be suspected that some of the neonatal complications of diabetic 
foetopathy (e.g. alterations in body composition and anthropometrical 
parameters) may be explained by the pathophysiological influence of the 
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TNF-system and leptin. Therefore, in a case-control cross-sectional study we 
measured maternal serum AHSG, TNF-, soluble TNF-receptor-1 and -2 
(sTNFR-1 and sTNFR-2) and leptin concentrations in healthy pregnant women 
being in different trimesters of the pregnancy and in patients with gestational 
diabetes mellitus (GDM). The relationship between indirect parameters of 
maternal insulin resistance (fasting C-peptide level, C-peptide/fasting blood 
glucose ratio) and the concentration of the above mentioned proteins were 
studied. Different anthropometric parameters of the neonates (body length, body 
weight and head circumference) were compared to the maternal cytokine and 
AHSG levels. 
 
 
Subjects and Methods 
 
One hundred and four healthy pregnant women (35 in the first, 31 in the second, 
and 38 in the third trimester), 30 GDM patients with high fasting C peptide 
levels in the 20-40th gestational weeks and 30 healthy age-matched non-pregnant 
females as a control group were investigated (Table 1). All participants gave 
their written informed consent. The diagnostic criteria of GDM were stated by a 
75 g oral glucose tolerance test (OGTT) according to the WHO classification 
[13] To maintain normoglycemia all of these patients required intensified insulin 
treatment (3 or more short acting shots, bedtime intermedier insulin). 
 
Anthropometric parameters (body weight, length and head circumference) of 30 
neonates (13 boys, 17 girls) of mothers with GDM, 23 newborns (11 boys, 12 
 6 
girls) delivered by healthy pregnant women between the 38th-40th week in the 
third trimester have been analyzed in correlation with the maternal clinical and 
laboratory parameters. All deliveries of the mothers with GDM also succeeded 
between the 38th-40th gestational weeks. Table 2 shows the anthropometric 
parameters of neonates. 
 
Serum AHSG concentration was determined by radial immunodiffusion using a 
monospecific goat anti-human AHSG antibody (IgG fraction, Incstar, Cat No. 
81931, 13.7 mg/ml, in a final concentration of 84 l/11.5 ml gel, mean 
coefficient of variance, IACV: 3.6%, mean interassay coefficient of variance, 
IECV: 6.2%). Tumor necrosis factor- (Sigma, St.Louis, MI, USA, IACV: 
4.8%, IECV: 6.7%), sTNFR-1 (Bender MedSystem, Vienna, Austria, IACV: 
1.9%, IECV: 8.6%), sTNFR-2 (Bender MedSystem, Vienna, Austria, IACV: 
1.4%, IECV: 2.0%), leptin (DRG International, USA, IACV: 4.6%, IECV: 
6.6%) concentrations were determined by ELISA, serum fasting C-peptide 
concentration by RIA (Biodata, Rome, Italy, IACV: 5.6%, IECV: 7.3%, normal 
fasting range 0.66-2.50 ng/ml). HbA1c was measured by HPLC (BioRad, normal 
value at non-diabetics 4.3-5.8%), serum fructosamine by Boehringer 
(Mannheim, Germany) automatic analyzer kit (normal value at non-pregnant 
non-diabetics 185-280 mol/l). The statistical analysis was performed by the 
Mann-Whitney linear correlation (Spearman), and multivariate analysis using 
the SPSS v10 statistical program. 
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Results 
 
Serum AHSG concentrations in non-pregnant and pregnant women and in 
patients with gestational diabetes mellitus 
Compared to non-pregnant women there was an increase of serum AHSG 
concentration during the first, second, and third trimesters of pregnancy (Figure 
1). In patients with GDM significantly elevated AHSG levels were observed 
compared to non-pregnant controls and of healthy pregnant women at any 
trimester (Figure 1). 
 
Significantly elevated (p  0.01) serum TNF-, sTNFR-1, sTNFR-2, leptin and 
C-peptide levels were found in GDM patients as compared to healthy 
non-pregnant controls and healthy pregnant females at any trimester (Table 3). 
In healthy pregnant females these values were also significantly higher (p  
0.01) in the third trimester compared to the first and second ones and to the 
non-pregnant controls (Table 3). 
 
Correlation between maternal serum AHSG concentration and the indirect 
parameters of insulin resistance 
There was a significant positive correlation between serum AHSG concentration 
and the indirect parameters of maternal insulin resistance (fasting C-peptide 
concentration and C-peptide/ Blood glucose ratio) in GDM patients and in 
healthy pregnant women (Table 4). Maternal serum AHSG concentration was 
also found to be in a linear positive correlation with the maternal serum TNF- 
and leptin values in the GDM group and in the healthy pregnant groups. These 
correlations were not observed in non-pregnant controls (Table 4). 
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Multivariate analysis showed that TNF- had a significant effect on AHSG 
concentrations both in GDM (r = 0.781, p < 0.0001) and in normal pregnancy (r 
= 0.737, p = 0.004). In this analysis, AHSG alone did not have a significant 
effect on indirect parameters of insulin resistance (Cp and Cp/Blood sugar ratio), 
however, in combination with TNF- and leptin it had a significant effect in 
GDM (adjusted r2 = 0.575, p = 0.001) and in normal pregnancy (adjusted r2 = 
0.823, p < 0.001). 
 
Correlation between maternal serum AHSG concentration and the 
anthropological parameters of newborns 
The anthropological parameters of neonates (both sexes) delivered by the GDM 
mothers were slightly decreased as compared to those delivered by healthy 
pregnant women (Table 2).  
 
Body length and head circumference of the newborns were found to be in a 
significant negative correlation with the maternal AHSG concentration in GDM 
(Table 5). In healthy pregnant women a significant negative linear correlation 
was calculated with all three anthropological parameters of the newborns (Table 
5). Among body length (bl), head circumference (hc), body weight (bw) of the 
newborns and maternal serum TNF- (rhc = - 0.4857, 95% C.I. = -0.7254 - 
-0.1411) and leptin (rbl: -0.4376, 95% C.I. = -0.6951 - -0.0807 p = 0.0156; rbw = 
-0.3706, 95% C.I. = -0.6513 - -0.0007, p = 0.0438) levels significant negative 
correlations have been calculated in the GDM group. In healthy pregnant 
women a significant negative linear correlation was observed only between 
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maternal leptin concentration and the head circumference of the neonates (r = 
-0.6001, 95% C.I.: -0.8283 - -0.2010, p = 0.0026). 
 
Multivariate analysis showed that maternal serum AHSG concentration alone 
did not have a significant influence neither on head circumference nor on body 
length of neonates in GDM and normal pregnancy. However, in combination 
with TNF-, leptin and C-peptide AHSG had a significant effect on these 
parameters in GDM (adjusted r2 = 0.563, p = 0.002), but not in normal 
pregnancy (adjusted r2 = -0.069, p = 0.583). 
 
 
Discussion 
 
The increase of maternal serum AHSG concentration during pregnancy has been 
observed but not analyzed and interpreted in details [14]. AHSG is considered as 
a negative acute phase reactant, the concentration of which decreases during 
infections, trauma and liver cirrhosis [15, 16, 17]. It is tempting to speculate the 
biological significance of this protein in clinical settings where its concentration 
increases, i.e. in pregnancy. 
 
The aim of the present study was to investigate the role of AHSG in maternal 
insulin resistance in GDM and in normal pregnant women. The phosphorylated 
variant of AHSG was described among the first proteins, which interfere with 
the intracellular signaling of the insulin receptor [1, 2, 3, 4, 5]. No relationship 
between serum AHSG levels and any parameters of insulin resistance has been 
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described so far. Only the phosphorylated form of AHSG is able to inhibit 
insulin signaling in vitro, the dephosphorylated form is inactive [3, 5]. AHSG 
isolated from human serum still retains some inhibitory activity on insulin 
receptor signaling, yet this activity is much less than that of recombinant AHSG 
produced in the baculovirus expression vector system [3]. The presence of 
phosphorylated AHSG in human serum (approximately 20% of the total) has 
been recently been demonstrated in healthy persons [18]. 
 
During the course of normal pregnancy increasing insulin resistance occurs, 
which is even more pronounced in GDM. Previously we found that the 
progressive elevation of the fasting C-peptide and C-peptide/Blood glucose ratio 
are easily measurable parameters of progressive insulin resistance in normal 
pregnancy and in GDM (due to ethical reasons clamp or other iv models for 
exact estimation of insulin resistance were not performed in our subjects) [19]. 
Therefore we considered these states as a model to study the contribution of 
different parameters (e.g. TNF-system, leptin and also AHSG) to the transitory 
insulin resistance. 
 
We found significant positive correlations among the TNF-system, leptin, 
AHSG, and the indirect parameters of insulin resistance in both healthy pregnant 
women and GDM patients. These data suggest the contribution of the elevated 
AHSG levels to insulin resistance. The liver is the main site of AHSG synthesis, 
however in pregnancy the foetoplacental unit can be an other source of the 
protein. This is supported by the elevation of the protein concentration during 
the course of pregnancy, especially in marked in the third trimester. In adults 
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AHSG can be expressed not only in the liver but in other organs, thus in the 
endometrium. In addition, autoantibodies against endometrial AHSG and 
transferrin have been demonstrated in patients with endometriosis [20]. An 
increased hepatic synthesis during pregnancy, however, cannot be ruled out. Our 
observations may suggest that this increased synthesis of AHSG in the liver 
contributes to the decreased hepatic insulin sensitivity during normal pregnancy 
and GDM. TNF- may also have a regulatory role on the synthesis of the 
protein. 
 
The negative correlation between maternal serum leptin, TNF- and head 
circumference of the newborns may raise the possibility that these cytokines can 
serve as negative regulators of the neonatal bone development, as it was 
suggested earlier in animal models [8, 9]. The negative regulatory role of AHSG 
on bone development has also been postulated, e.g. AHSG prevented bone 
resorption and hydroxylapatite formation in vitro [21, 22]. The biological 
significance of AHSG in the regulation in human neonatal bone development 
has not been clarified, however, several data from animal studies including mice 
knocked out for AHSG gene raise the possibility that the protein may prevent 
unwanted calcification [22]. The negative correlation between the AHSG 
concentrations measured in maternal serum during normal pregnancy and GDM 
and the head circumference of the neonates further supports the hypothesis of 
the negative regulatory role of the protein in human neonatal bone development. 
Further studies are necessary to the exact role of AHSG in this process.  
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In conclusion, AHSG, TNF- and leptin in combination may contribute to 
insulin resistance during normal pregnancy and GDM. These cytokines and 
AHSG may also negatively regulate the neonatal skeletal development. 
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Table 1. Clinical and laboratory parameters of healthy pregnant women, patients 
with gestational diabetes mellitus patients and non-pregnant controls (mean  
SD) 
 
 GDM patients Healthy 
pregnant 
women 
Non-pregnant 
women 
n 30 104 30 
Age (years) 28.0 ± 2.8 27.8 ± 2.8 28.3 ± 3.5 
Gestational age (week) 27.67 ± 6.1 24.3 ± 13.6  
Body mass index (kg/m2) 33.4 ± 6.4* 25.8 ± 2.7 22.9 ± 2.5 
Fasting blood glucose 
concentration (mmol/l) 
4.70 ± 1.50 4.48 ± 0.37 4.48 ± 0.27 
Fasting C-peptide (ng/ml) 6.00 ± 3.01 1.85 ± 0.97 1.11 ± 0.82 
C-peptide/Blood glucose 
ratio 
0.40 ± 0.15 1.27 ± 0.51 0.27 ± 0.13 
HbA1c(%) 5.11 ± 0.71 5.30 ± 0.80 4.96 ± 0.45 
Serum fructosamine 
concentration (mol/l) 
203.3 ± 15.4 191.0 ± 18.5  
Daily insulin dose (U) 33.30 ± 20.83   
Daily insulin dose/Body 
weight (U/kg) 
0.41 ± 0.21   
 
n: number of cases, *: p  0.01 as compared to values of healthy pregnant 
women, calculated by the Mann-Whitney test. 
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Table 2. Anthropometric parameters, absolute values and percentiles of the 
newborns (mean  SD) 
 
 NEWBORNS 
 of patients with 
gestational diabetes 
mellitus 
n = 30 
of healthy pregnant 
women 
n = 23 
Boys/girls 13 / 17 11 / 12 
Body weight (g) 3151 ± 672* 3575 ± 365 
Percentile 55.87 ± 30.29 64.75 ± 16.10 
Body length (cm) 51.90 ± 3.40* 55.80 ± 2.80 
Percentile 86.4 ± 31.88 110.90 ± 16.24 
Head circumference 
(cm) 
33.80 ± 1.70* 34.75 ± 1.15 
Percentile 65.50 ± 22.84 71.30 ± 32.14 
 
n: number of cases, *: p  0.01 as compared to neonates of healthy pregnant 
women calculated by the Mann-Whitney test. 
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Table 3. Serum tumor necrosis factor (TNF)-, soluble TNF-receptor-1 and -2 
(sTNFR-1 and sTNFR-2), leptin, fasting C-peptide concentrations and the 
C-peptide/Blood glucose ratio in patients with gestational diabetes mellitus 
(GDM), different trimesters of the healthy pregnant group and non-pregnant 
control females (mean  SD) 
 
 GDM Healthy pregnant women Non-pregn
ant 
controls 
 1st 2nd 3rd 
  trimester  
Serum TNF- 
(pg/ml) 
6.3 ± 
0.6** 
4.1 ± 
0.4#+ 
4.4 ± 
0.4#+ 
5.5 ± 0.7* 4.1 ± 0.4 
Serum sTNFR-1 
(ng/ml) 
3.2 ± 0.5* 2.1 ± 
0.5#+ 
2.3 ± 
0.5#++ 
2.8 ± 
0.9** 
2.01 ± 0.1 
Serum sTNFR-2 
(ng/ml) 
10.0 ± 
6.9** 
4.7 ± 
2.1#+ 
5.3 ± 
3.7#++ 
5.7 ± 
2.6** 
3.3 ± 0.2 
Serum leptin 
(ng/ml) 
40.4 ± 
24.5** 
11.4 ± 
7.2#+ 
11.1 ± 
5.2#+ 
33.5 ± 
22.0** 
12.0 ± 9.1 
Serum fasting 
C-peptide 
6.0 ± 
3.0** 
1.2 ± 
0.8#+ 
1.3 ± 
0.4#+ 
3.1 ± 1.7* 1.1 ± 0.8 
Fasting 
C-peptide/Blood 
glucose ratio 
1.4 ± 
0.5** 
0.3 ± 
0.1#+ 
0.3 ± 
0.1#+ 
0.7 ± 0.2* 0.2 ± 0.1 
 
 20 
*: p < 0.05, **: p < 0.01, as compared to the non-pregnant controls, #: p < 0.01, 
as compared to patients with GDM, +: p < 0.05, ++: p <0.01, as compared to 
pregnant women in the third trimester, calculated by the Mann-Whitney test. 
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Table 4. Correlation between fetuin/2-HS-glycoprotein concentration and 
laboratory parameters of patients with gestational diabetes mellitus (GDM), 
healthy pregnant women, and non-pregnant controls 
 
 GDM Healthy pregnant 
women 
Non-pregnant 
controls 
 n = 30 n = 38 n = 30 
Body mass index 0.5702# 
0.2537 – 0.7764 
(0.0010) 
0.2180 
-0.1099 – 0.5030 
(0.1766) 
-0.0021 
-0.3884 – 0.3513 
(0.9104) 
Tumor necrosis 
factor- 
0.6614 
0.3858 – 0.8286 
(< 0.0001) 
0.5853 
0.3263 – 0.7625 
(< 0.0001) 
-0.0541 
-0.3224 – 0.4158 
(0.7766) 
sTNFR-1 0.0308 
-0.3432 – 0.3963 
(0.8718) 
0.3956 
0.0836 – 0.6353 
(0.0115) 
-0.0091 
-0.3779 – 0.3621 
(0.9618) 
sTNFR-2 0.1003 
-0.2802 – 0.4535 
(0.5981) 
0.2123 
-0.1157 – 0.4986 
(0.1884) 
0.0318 
-0.3422 – 0.3972 
(0.8673) 
Leptin 0.5775 
0.2639 – 0.7807 
(0.0008) 
0.3528 
0.0368 – 0.6047 
(0.0255) 
-0.1212 
-0.4702 – 0.2605 
(0.5233) 
C-peptide 0.6699 
0.3988 – 0.8334 
(< 0.0001) 
0.4020 
0.0939 – 0.6398 
(0.0101) 
0.0519 
-0.3244 – 0.4139 
(0.7855) 
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C-peptide/Blood 
glucose ratio 
0.5116 
0.0939 - 0.6398 
(0.0039) 
0.3241 
0.0044 – 0.5867 
(0.0413) 
0.2151 
-0.1683 – 0.5420 
(0.2537) 
 
#: calculated by the Spearman’s rank correlation. First row: correlation 
coefficient, second row: 95% confidence interval. Significance values are in 
brackets in the third row. n: number of cases, sTNFR-1: soluble tumor necrosis 
factor receptor 1, sTNFR-2: soluble tumor necrosis factor receptor 2. 
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Table 5. Correlation between fetuin/2-HS-glycoprotein concentration and 
anthropological parameters of the neonates of patients with gestational dibetes 
mellitus (GDM) and healthy pregnant women 
 
 GDM Healthy pregnant 
women 
 n = 30 n = 23 
Head circumference  -0.6256# 
-0.8085 - -3325 
(0.0002) 
-0.6417 
-0.8374 - -0.3003 
(0.0010) 
Body length -0.4068 
-0.6752 - -0.0433 
(0.0257) 
-0.5016 
-0.7628 - -0.0998 
(0.0147) 
Body weight -0.3098 
-0.6099 – 0.0680 
(0.0957) 
-0.4998 
-0.7773 - -0.0594 
(0.0248) 
 
# Calculated by the Spearman’s rank correlation. First row: correlation 
coefficient, second row: 95% confidence interval. Significance values are in 
brackets in the third row. n: number of cases. 
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Figure legend: 
 
Figure 1. Serum fetuin/2HS-glycoprotein concentrations in different trimesters 
(I, II, III) of normal pregnancy, third trimester of gestation diabetes (GDM) and 
non-pregnant women (NP). Horizontal lines within scattergram represent 
means. Statistical differences between individual groups, represented by 
horizontal lines between groups were calculated by the Mann-Whitney test. 
 
